文献速递胸部肿瘤放疗

荷兰I-III期肺癌根治性放疗后的90天死亡率

Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands.
PubMed 文献 · Radiother Oncol · 2024-12-06

该回顾性人群研究基于荷兰国家癌症登记处2015-2020年18,355例I-III期肺癌患者,分析根治性(放)化疗后90天死亡率。I-II期90天死亡率为2.56%,III期为4.60%;男性、老年及体力状态差者死亡率显著更高,与机构规模无关。I-II期立体定向放疗低于常规放疗(2.0% vs 5.25%,OR 0.5),III期同步放化疗低于序贯放化疗(3.4% vs 5.9%)。

要点

  • I-II期肺癌根治性放疗后90天死亡率为2.56%,III期为4.60%。
  • I-II期立体定向放疗90天死亡率低于常规放疗(2.0% vs 5.25%,OR 0.5)。
  • III期同步放化疗90天死亡率低于序贯放化疗(3.4% vs 5.9%,OR 1.5)。

核心结论

  • 荷兰根治性放疗后肺癌短期死亡率较低,且与机构规模无关。
  • 90天死亡率作为放疗质量监测指标存在争议,需标准化定义及病案组合因素。

研究设计与样本

  • 回顾性人群研究,查询荷兰国家癌症登记处数据。
  • 纳入2015年至2020年接受根治性(放)化疗的I-III期肺癌患者18,355例。
  • 从放疗开始和放疗结束分别计算早期死亡率并报告95%CI。
  • 采用多变量逻辑回归分析临床特征与90天死亡率的关系。

主要发现

  • I-II期90天死亡率为2.56%,III期为4.60%。
  • 男性、老年及体力状态差者90天死亡率显著更高,与机构规模无关。
  • I-II期立体定向放疗90天死亡率2.0% vs 常规放疗5.25%(OR 0.5,95%CI 0.4-0.7)。
  • III期90天死亡率从2015-2016年5.26%降至2019-2020年3.73%(OR 0.7,95%CI 0.5-0.9)。
  • III期同步放化疗90天死亡率3.4% vs 序贯放化疗5.9%(OR 1.5,95%CI 1.2-1.9)。

关键数值与推荐

  • 从放疗结束计算,I-II期早期死亡率增至3.20%,III期增至6.70%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The 90-day mortality following lung cancer treatment is a common performance indicator. The aim of this study was to investigate 90-day mortality following (chemo)radiotherapy for stage I-III lung cancer to evaluate the applicability of this outcome indicator in this patient population. MATERIALS AND METHODS: The Netherlands National Cancer Registry was queried for this retrospective population-based study. Early mortality rates from the start and end of radiotherapy are reported with 95% confidence intervals (CI). The association between clinical characteristics and 90-day mortality was evaluated with multivariable logistic regression analysis. RESULTS: 18,355 Patients treated between 2015 and 2020 were included. The 90-day mortality was 2.56% in stages I-II and 4.60% in stage III, was significantly higher in males, elderly patients and patients with a poor performance status and independent of facility volume. In stage I-II, 90-day mortality was lower after stereotactic versus conventional radiotherapy (2.0% versus 5.25%, OR 0.5 (95%CI 0.4-0.7)). In stage III, mortality decreased from 5.26% in 2015-2016 to 3.73% in 2019-2020 (OR 0.7 (95% CI 0.5-0.9)) and was lower after concurrent versus sequential chemoradiotherapy (3.4% versus 5.9%, OR 1.5 (95%CI 1.2-1.9)). Early mortality increased to 3.20% in stages I-II and 6.70% in stage III when calculated from the end of radiotherapy. CONCLUSION: Short-term mortality rates following curative intent radiotherapy for lung cancer in the Netherlands are low and independent of facility volume. It was demonstrated that 90-day mortality is an arguable indicator to monitor radiotherapy quality and that standardization of definitions and relevant case-mix factors is warranted.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. van Doorn-Wink KCJ, Postmus PE, de Ruysscher D, et al. Ninety-day mortality following curative intent radiotherapy for stage I-III lung cancer in the Netherlands. Radiother Oncol. 2024. PMID: 39647529. doi:10.1016/j.radonc.2024.110661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。